Industry Focus

Here's why post-approval setbacks have caused Puma Biotechnology, Clovis Oncology, and Regenxbio shares to tumble, and if any of these stocks are finally worth buying. Stocks: PBYI, CLVS, RGNX

Check out more of our content here:

Direct download: 20191009_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EST

1